EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls

Rabab Alkhayyat iD, Areeg Abbas, Cecily M Quinn iD, Emad A Rakha iD

Histopathology · 2024-04 · 84 (5) · 723-741

DOI: 10.1111/his.15101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 27.11.2023. Verfasst von Rabab Alkhayyat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospitals, Nottingham, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Tumor Suppressor Proteins, Breast. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour protein 63 (p63) is a transcription factor of the p53 gene family, encoded by the TP63 gene located at chromosome 3q28, which regulates the activity of genes involved in growth and development of the ectoderm and derived tissues. p63 protein is normally expressed in the nuclei of the basal cell layer of glandular organs, including breast, in squamous epithelium and in urothelium. p63 immunohistochemical (IHC) staining has several applications in diagnostic breast pathology. It is commonly used to demonstrate myoepithelial cells at the epithelial stromal interface to differentiate benign and in situ lesions from invasive carcinoma and to characterize and classify papillary lesions including the distinction of breast intraduct papilloma from skin hidradenoma. p63 IHC is also used to identify and profile lesions showing myoepithelial cell and/or squamous differentiation, e.g. adenomyoepithelioma, salivary gland‐like tumours including adenoid cystic carcinoma, and metaplastic breast carcinoma including low‐grade adenosquamous carcinoma. This article reviews the applications of p63 IHC in diagnostic breast pathology and outlines a practical approach to the diagnosis and characterization of breast lesions through the identification of normal and abnormal p63 protein expression. The biology of p63, the range of available antibodies with emphasis on staining specificity and sensitivity, and pitfalls in interpretation are also discussed. The TP63 gene in humans, which shows a specific genomic structure, resulting in either TAp63 (p63) isoform or ΔNp63 (p40) isoform. As illustrated in the figure, both isoforms contain a DNA‐binding domain (Orange box) and an oligomerization domain (Grey box). TAp63 contains an N‐terminal transactivation (TA) domain (Green box), while ΔNp63 has an alternative terminus (Yellow box). Antibodies against conventional pan‐p63 (TP63) bind to the DNA binding domain common to both isoforms (TAp63 and p40) and does not distinguish between them. Antibodies against TAp63 bind to the N‐terminal TA domain, while antibodies specific to ΔNp63 (p40) bind to the alternative terminus. Each isoform has variant isotypes (α, β, γ, δ, and ε).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTumor Suppressor ProteinsBreastFemaleHumansDNAImmunohistochemistryProtein IsoformsAnimalsTranscription Factors

Stichwörter der Autor:innen

applicationbreast pathologyimmunohistochemistryp63pitfalls

Substanzen

DNAProtein IsoformsTumor Suppressor ProteinsTP63 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospitals, Nottingham, UK.
  • Department of Pathology, Salmaniya Medical Complex, Government Hospitals, Manama, Kingdom of Bahrain.
  • Irish National Breast Screening Program, Department of Histopathology, St. Vincent's University Hospital, Dublin, School of Medicine, University College Dublin, Dublin, Ireland.
  • Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
  • Department of Pathology, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.

ORCID-Profile: Rabab Alkhayyat, Cecily M Quinn, Emad A Rakha

Zitieren

APA

Alkhayyat, R., Abbas, A., Quinn, C. M., & Rakha, E. A. (2024). Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls. Histopathology, 84(5), 723-741. https://doi.org/10.1111/his.15101

Vancouver

Alkhayyat R, Abbas A, Quinn CM, Rakha EA. Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls. Histopathology. 2024;84(5):723-741. doi:10.1111/his.15101

BibTeX
@article{Alkhayyat2024,
  author = {Alkhayyat, Rabab and Abbas, Areeg and Quinn, Cecily M and Rakha, Emad A},
  title = {Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls},
  journal = {Histopathology},
  year = {2024},
  volume = {84},
  number = {5},
  pages = {723--741},
  doi = {10.1111/his.15101}
}
Kostenlos starten →